Drug Profile
Verzistobart - Agenus
Alternative Names: Anti-TIM-3 monoclonal antibody - Agenus; INCAGN-02390; INCAGN-2390Latest Information Update: 26 Nov 2023
Price :
$50
*
At a glance
- Originator Agenus; Ludwig Institute for Cancer Research
- Developer Agenus; Incyte Corporation; University of Washington
- Class Antineoplastics; Immunoglobulin Fc fragments; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; HAVCR2 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Endometrial cancer; Squamous cell cancer
- Phase I/II Malignant melanoma; Solid tumours
- Phase I Cancer; Merkel cell carcinoma
Most Recent Events
- 19 Oct 2023 Phase-I clinical trials in Merkel cell carcinoma (Late-stage disease, Second-line therapy or greater, Combination therapy, Refractory metastatic disease) in USA (IV) (NCT06056895)
- 02 Jun 2023 Efficacy and adverse events data from a phase I/II trial in Solid tumours and Malignant melanoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 09 Mar 2023 Phase-II clinical trials in Endometrial cancer in Unknown location (IV) before March 2023 (Agenus pipeline; March 2023)